Trials / Unknown
UnknownNCT02780778
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase II, Open-label, single arm, exploratory study is to evaluate the efficacy and the safety of Apatinib（500mg/d）with docetaxel (60 mg/m²) in advanced Non-squamous Non-small cell lung cancer after failure of first line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Targeted therapy Apatinib：500 mg，po，qd |
| DRUG | Docetaxel | chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2016-05-23
- Last updated
- 2016-05-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02780778. Inclusion in this directory is not an endorsement.